EURbG2: A European prospective study of unilateral retinoblastoma requiring enucleation, first-line or after neoadjuvant chemotherapy, with assessment of histological risk factors and biomarkers
Sponsor: Institut Curie
Phase:
Disease: Unilateral retinoblastoma
EU trial number: 2024-515962-15-00
Population: Predominantly pediatric patients with extensive non-familial unilateral intraocular retinoblastoma requiring first-line enucleation (Study A), or advanced unilateral retinoblastoma requiring neoadjuvant chemotherapy before enucleation (Study B), with subsequent risk-adapted adjuvant treatment.
Register Investigator Interest
Interested in offering this trial to suitable patients?